» Articles » PMID: 26782036

Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

Abstract

Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD), an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). Recently, we organized an international collaborative group called American and European NEtwork of Antisynthetase Syndrome (AENEAS) for the study of this rare and fascinating disease. The group collected and published one of the largest series of ASSD patients ever described and with one of the longer follow-up ever reported. The number of participating centers is steadily increasing, as well as the available cohort. In the first paper, we showed that arthritis, myositis, and ILD may be frequently the only feature at disease onset, raising problems to reach a correct diagnosis of this syndrome. Nevertheless, we first observed that the ex novo appearance of further manifestations is common during the follow-up, strengthening the importance of a correct diagnosis. In our cohort, the 24 % of the 243 patients up to now collected had isolated arthritis as a presenting feature. These patients represent the most intriguing group in terms of differential diagnosis and clinical time course. Furthermore, data on this aspect are scanty, the reason that lead us to evaluate these aspects in our cohort of patients, reviewing also available literature. In fact, the most relevant aspect is that ASSD is rarely suspected in this setting of patients, in particular in case of poliarticular involvement, positive rheumatoid factor (RF), or anti-cyclic citrullinated peptide antibodies (ACPA) or evidence of joint erosions at plain radiographs. These findings were not rare in our cohort, and they have been also described in other series. Furthermore, manifestations such as Raynaud's phenomenon, mechanic's hands, and fever that may lead to the suspect of ASSD are observed only in a third of cases. If we consider the high rate of clinical picture progression in these patients, we feel that ASSD should be carefully considered in all patients presenting with isolated arthritis, even in those with erosive, RF, and ACPA-positive arthritis.

Citing Articles

Anti-PL-7/PL-12 antisynthetase syndrome associated with interstitial lung disease following SARS-COV-2 infection and vaccination: A case study review.

Garcia-Bravo L, Villegas A, Lopez Uceda B, Mariscal A, Vadillo C, Nieto Barbero M Heliyon. 2025; 11(2):e41311.

PMID: 39906838 PMC: 11791273. DOI: 10.1016/j.heliyon.2024.e41311.


A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.

Patel P, Marinock J, Ajmeri A, Brent L Int J Mol Sci. 2024; 25(8).

PMID: 38674039 PMC: 11050089. DOI: 10.3390/ijms25084453.


Dermatomyositis: Practical Guidance and Unmet Needs.

Cassard L, Seraly N, Riegert M, Patel A, Fernandez A Immunotargets Ther. 2024; 13:151-172.

PMID: 38464459 PMC: 10924937. DOI: 10.2147/ITT.S381472.


High expression of VARS promotes the growth of multiple myeloma cells by causing imbalance in valine metabolism.

Shi R, Du W, He Y, Hu J, Yu H, Zhou W Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(6):795-808.

PMID: 37587064 PMC: 10930441. DOI: 10.11817/j.issn.1672-7347.2023.220602.


Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies.

Choi M, Satoh M, Fritzler M Curr Opin Rheumatol. 2023; 35(6):383-394.

PMID: 37503636 PMC: 10552841. DOI: 10.1097/BOR.0000000000000957.


References
1.
Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9):1580-8. DOI: 10.1136/ard.2010.138461. View

2.
Stone K, Oddis C, Fertig N, Katsumata Y, Lucas M, Vogt M . Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007; 56(9):3125-31. DOI: 10.1002/art.22865. View

3.
Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C . Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012; 11(10):739-45. DOI: 10.1016/j.autrev.2012.01.006. View

4.
Connors G, Christopher-Stine L, Oddis C, Danoff S . Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest. 2010; 138(6):1464-74. DOI: 10.1378/chest.10-0180. View

5.
Satoh M, Tanaka S, Ceribelli A, Calise S, Chan E . A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol. 2015; 52(1):1-19. PMC: 5828023. DOI: 10.1007/s12016-015-8510-y. View